Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 21, 2012

Adding Risedronate Adds No Benefit in Castration-Resistant Prostate Cancer

European Journal of Cancer

 

Additional Info

European Journal of Cancer
Randomised Phase II/III Study of Docetaxel With or Without Risedronate in Patients With Metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)
Eur. J. Cancer 2012 Jun 08;[EPub Ahead of Print], HJ Meulenbeld, ED van Werkhoven, JLLM Coenen, GJ Creemers, OJL Loosveld, PC de Jong, AJ ten Tije, SD Fossa, M Polee, W Gerritsen, O Dalesio, R de Wit

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.


Further Reading